Josefine Krüger
Charité Universitätsmedizin, Berlin, Germany
GCK inhibition as a new therapeutical approach in RASMut myeloma and possible strategy to overcome therapy resistance
View More
Silvia Armuzzi
University of Bologna, Italy
DESTINY – Detecting Spatial Heterogeneity in Multiple Myeloma patients through a Liquid Biopsy approach
View More
Marína Levy
University of Iceland
Investigating the Impact of Vaccinations on the Development and Course of Monoclonal Gammopathies: A Comprehensive Analysis
View More
Eduarda Barbosa
Federal University of Rio de Janeiro
Flow cytometry as a tool for the study of the tumor microenvironment in multiple myeloma
View More
Ross Firestone
Memorial Sloan Kettering Cancer Center
Characterizing the emergence of T cell dysfunction as a cause of therapy failure and disease progression in multiple myeloma
View More
Lili Sophie Sester
University of Heidelberg, Germany
DISCOVER NUTRIENTS – Understanding the relationship between nutrition and microbiome in MM
View More
Kiyosumi Ochi
The Institute of Medical Science, The University of Tokyo, Japan
A scalable manufacturing platform for externally controllable universal CAR T-cell products
View More
Josefine Krüger
Charité Universitätsmedizin, Berlin, Germany
Investigation of the molecular mechanism of GCK-inhibition as therapeutic approach in multiple myeloma
View More
David Garrido
Hospital de Clínicas Dr. Manuel Quintela, Montevideo, Uruguay
Evaluation of single nucleotide variants in DNA repair and cell cycle control genes in multiple myeloma patients undergoing hematopoietic stem cell transplant and their association with clinical outcomes
View More
Sara Taranto
University of Brescia, Italy
Investigating CREB1 signaling as a novel therapeutic target in multiple myeloma
View More
Florentin Späth
Umeå University, Sweden
Biomarkers for monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma
View More
Andrea Poletti
University of Bologna, Italy
Ancestrality of genomic alterations in Multiple Myeloma: impact on the clonal evolution and on the Minimal Residual Disease dynamics
View More
Smith Giri
University of Alabama Birmingham
Optimizing Melphalan dose among older adults with Multiple Myeloma receiving Autologous Stem Cell Transplantation
View More
David Garrido
Hospital de Clínicas "Dr. Manuel Quintela", Uruguay
Evaluation of single nucleotide polymorphisms of BRCA1, CDKN1A, TP53BP, and XRCC1 in multiple myeloma patients undergoing hematopoietic stem cells transplant and their association with clinical outcomes
View More
Sara Gandfoli
Hematology Research Unit, University of Helsinki, Finland
Investigating the molecular mechanisms of microenvironment-dependent immune escape to natural killer cells in myeloma to uncover biomarkers for rational combination treatment strategie
View More
Lucia Chen
Weatherall Institute of Molecular Medicine, United Kingdom
Immune cell contribution to drug-resistance in Multiple Myeloma
View More
Urvi Shah
Memorial Sloan Kettering Cancer Center, New York, NY
Spatial and temporal tumor genomic heterogeneity in extramedullary multiple myeloma and solitary plasmacytoma with minimal marrow involvement
View More
Teoh Phaik Ju
University of Singapore, Singapore
Systematic functional genomics characterization of 17p13(del) multiple myeloma
View More
Laura Notarfranchi
University of Parma, Italy
Role of flow cytometry and especially its use in the definition of the measurable residual disease (MRD) in multiple myeloma
View More
Elias Mai
Heidelberg University Hospital, Germany
Patterns of relapse from complete response during different maintenance strategies
View More
Sara Gandfoli
Dana-Farber Cancer Institute, Boston, MA
Dissecting the mechanisms of Multiple Myeloma (MM) resistance to Natural Killer (NK) cells and the role of NK cells-macrophage interaction in MM immune-evasion
View More
Marc-Andrea Bärtsch
Heidelberg University Hospital, Germany
Deciphering the human plasma cell niche and its transformation in multiple myeloma by highly multiplexed tissue imaging
View More
Jean-Baptiste Alberge
Center for Research in Cancerology and Immunology Nantes-Angers, France
The permissive immune microenvironment is a critical regulator of disease progression from SMM to overt MM, and defining these alterations is critical for the development of translational prognostic and mechanistic models of disease progression
View More
Why Become a Member
The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.
The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.
